This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.62% per year. These returns cover a period from January 1, 1988 through June 2, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
SRPT Down After Third Death in Muscular Dystrophy Gene Therapy Program
by Zacks Equity Research
Sarepta plummets after a third death in its muscular dystrophy program for investigational gene therapies, prompts FDA action and intensifies safety scrutiny.
RHHBYNegative Net Change BAYRYPositive Net Change SRPTNegative Net Change VRNAPositive Net Change
biotechnology biotechs gene-therapy medical pharmaceuticals
VTRS Down on Late-Stage Study Failure of Eye Disease Drug
by Zacks Equity Research
VTRS slides after phase III trial failure for blepharitis drug MR-139, adding pressure to an already struggling stock.
JNJPositive Net Change BAYRYPositive Net Change VTRSPositive Net Change
biotechnology biotechs medical pharmaceuticals
Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?
by Kinjel Shah
JNJ jumps over 6% on Q2 earnings beat and full-year guidance increase, driven by strong pharma sales and improved MedTech sales.
JNJPositive Net Change AMGNPositive Net Change TEVAPositive Net Change KVUEPositive Net Change
pharmaceuticals
J&J Expects Oncology Sales of USD 50B by 2030: Can It Achieve the Goal?
by Kinjel Shah
JNJ eyes $50B in oncology sales by 2030, driven by drugs like Darzalex, Erleada, new launches including Carvykti and Tecvayli, and its cancer pipeline.
AZNNo Net Change JNJPositive Net Change PFENegative Net Change MRKNegative Net Change
pharmaceuticals
Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock?
by Zacks Equity Research
KYMR jumps 70.7% in 3 months as the $750M oncology deal with GILD and pipeline advances in TPD drugs impress investors.
SNYNegative Net Change GILDPositive Net Change KYMRNegative Net Change
biotechnology biotechs medical pharmaceuticals
Regeneron Stock Plunges 22.6% YTD: Should You Buy, Sell or Hold?
by Zacks Equity Research
Eylea's sales slump and pipeline setbacks have dragged REGN down 22.8% YTD, underperforming its peers and the S&P 500.
REGNPositive Net Change SNYNegative Net Change RHHBYNegative Net Change BAYRYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Wegovy & Ozempic Drive Another Strong Quarter for Novo Nordisk?
by Ahan Chakraborty
Wegovy and Ozempic drive 66% of NVO's Q1 revenues - investors eye Q2 sales ahead of results on Aug. 6.
NVOPositive Net Change LLYNegative Net Change VKTXPositive Net Change
biotechnology biotechs medical pharmaceuticals
AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies
by Zacks Equity Research
AZN's anselamimab fails to meet key goals in late-stage AL amyloidosis trials despite signs of subgroup benefit.
AZNNo Net Change PRTAPositive Net Change AGENNegative Net Change AKRONegative Net Change
biotechs medical pharmaceuticals
MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights
by Zacks Equity Research
Madrigal Pharmaceuticals stock jumps 11% after securing a new U.S. patent for Rezdiffra's dosing, reinforcing exclusivity through 2044.
BAYRYPositive Net Change AGENNegative Net Change MDGLNegative Net Change VRNAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Recursion Pharmaceuticals Rises 6% in a Month: How to Play the Stock
by Ahan Chakraborty
RXRX gains 5.5% in a month on positive pipeline update; long-term hold advised given strong potential of its AI-driven drug discovery platform.
SNYNegative Net Change RHHBYNegative Net Change BAYRYPositive Net Change RXRXPositive Net Change
artificial-intelligence biotechnology biotechs medical oncology-screening pharmaceuticals
ETFs to Gain on JNJ's Solid Q1 Earnings & Upbeat Outlook
by Sweta Killa
IHE, PPH, XLV, IYH and FTXH could gain as JNJ lifts 2025 outlook and dividend after strong Q2 earnings beat.
JNJPositive Net Change XLVNegative Net Change IYHNegative Net Change IHENegative Net Change PPHNegative Net Change FTXHPositive Net Change
earnings etfs pharmaceuticals
SRPT Stock Soars on Unveiling New Restructuring Plan, Pipeline Pivots
by Zacks Equity Research
Sarepta's shares jump after unveiling a major restructuring plan to cut costs. The company shifts focus to siRNA and reprioritizes its pipeline.
RHHBYNegative Net Change SRPTNegative Net Change ARWRNegative Net Change
biofuels gene-editing gene-therapy medical pharmaceuticals
Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?
by Kinjel Shah
LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.
NVOPositive Net Change MRKNegative Net Change LLYNegative Net Change VERVPositive Net Change
pharmaceuticals
Novartis Beats on Q2 Earnings and Sales, CFO Retires, Stock Down
by Zacks Equity Research
NVS beats on Q2 earnings, raises 2025 income outlook on strong drug sales, but Cosentyx miss and CFO exit weigh on shares.
NVSPositive Net Change RHHBYNegative Net Change JNJPositive Net Change BAYRYPositive Net Change
biotechnology earnings medical pharmaceuticals
Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag
by Zacks Equity Research
SNY's SAR446597, a one-time intravitreal gene therapy, secures FDA fast track tag for geographic atrophy due to age-related macular degeneration.
SNYNegative Net Change APLSNegative Net Change ARVNPositive Net Change AKRONegative Net Change
pharmaceuticals
JNJ Begins Drug Sector Q2 Earnings With a Beat & Guidance Raise
by Zacks Equity Research
JNJ tops second-quarter estimates and raises 2025 guidance as Innovative Medicines outperforms and MedTech gains momentum.
JNJPositive Net Change AMGNPositive Net Change TEVAPositive Net Change KVUEPositive Net Change
pharmaceuticals
Strong Q2 Earnings, Cooling PPI Lead Pre-Markets Higher
by Mark Vickery
Headline PPI for June, month over month, reached 0.0% -- lower than the +0.2% expected and 30 bps below May.
GSNo Net Change BACPositive Net Change MSPositive Net Change JNJPositive Net Change
banking earnings inflation pharmaceuticals
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth?
by Ahan Chakraborty
RXRX is scaling its AI-driven drug discovery technology through billion-dollar pharma deals and strategic tech alliances.
SDGRPositive Net Change RLAYPositive Net Change RXRXPositive Net Change
artificial-intelligence biotechnology biotechs medical pharmaceuticals
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
by Kinjel Shah
Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.
CPRXPositive Net Change TBPHPositive Net Change ALDXPositive Net Change LRMRPositive Net Change ZVRANegative Net Change
pharmaceuticals
Will Increased Expenses Affect Bristol Myers' Performance?
by Ekta Bagri
BMY inks $3.5B bispecific antibody deal with BioNTech as top-line pressures and bottom-line risks mount.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change BNTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
How Will AbbVie's Oncology Drugs Aid Upcoming Q2 Results?
by Sundeep Ganoria
ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.
AZNNo Net Change PFENegative Net Change MRKNegative Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
BAYRY Skyrockets 62.9% YTD: Should You Buy or Sell the Stock?
by Zacks Equity Research
Bayer's shares are up 62.9% YTD as new drug approvals and a streamlined model fuel a sharp pharma turnaround.
REGNPositive Net Change JNJPositive Net Change BAYRYPositive Net Change
biotechnology medical pharmaceuticals
3 Medical Stocks to Watch as Q2 Earnings Approach: ABT, JNJ, NVS
by Shaun Pruitt
The broader market's historic rebound may make it necessary to consider some defensive positions in the portfolio, and these medical stocks fit the bill ahead of their Q2 reports.
ABTPositive Net Change NVSPositive Net Change JNJPositive Net Change
dividend-investing dividends earnings inflation investing large-cap medical medical-devices pharmaceuticals
Merck Starts Phase III Studies on Once-Monthly Pill for HIV Prevention
by Zacks Equity Research
MRK launches Phase III trials for its once-monthly HIV prevention pill MK-8527, aiming to rival Gilead's daily PrEP options.
GSKNo Net Change MRKNegative Net Change GILDPositive Net Change
biotechs medical pharmaceuticals
The Zacks Analyst Blog Highlights Lilly, Netflix, GE Aerospace, Willis Lease and Flanigan's Enterprises
by Zacks Equity Research
LLY, NFLX, and GE lead this week???s top research picks as strong demand, growth strategies, and sector tailwinds fuel performance.
GEPositive Net Change NFLXPositive Net Change LLYNegative Net Change WLFCPositive Net Change BDLNo Net Change
aerospace consumer-discretionary pharmaceuticals restaurants transportation